Constellation Pharmaceuticals, Inc. (CNST) |
| 33.99 0 (0%) 04-24 15:47 |
| Open: | 33.98 |
| High: | 34.03 |
| Low: | 33.97 |
| Volume: | 1,269,201 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 39.75 |
| Resistance 1: | 34.03 |
| Pivot price: | 33.91 |
| Support 1: | 33.75 |
| Support 2: | 33.58 |
| 52w High: | 39.3 |
| 52w Low: | 17 |
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Financials
| EPS | -3.040 |
| Book Value | 7.880 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -22.4 |
| Return on Equity (ttm) | -40.7 |
Company news
Fri, 24 Jan 2025
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma - ACCESS Newswire
Thu, 15 Jul 2021
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology - ACCESS Newswire
Fri, 11 Jun 2021
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib - GlobeNewswire
Fri, 04 Jun 2021
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting - GlobeNewswire
Mon, 06 Jan 2020
These Were the 10 Best Stocks of 2019 - The Motley Fool
Mon, 23 Dec 2019
These Were the 10 Best Healthcare Stocks of 2019 - The Motley Fool
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
